5 8 Mechanism of action of suzetrigine. Suzetrigine selectively inhibits the Nav1.8 peripheral sodium channel. inhibitor for the treatment of adults with moderate-to- severe acute pain. The recent study pointed out that Phase 3 trials have demonstrated that suzetrigine provides a statistically significant and clinically meaningful reduction in acute postoperative pain compared to placebo, with efficacy similar to hydrocodone/acetaminophen and a favor- able safety profile. Mechanistic studies confirm selec- tive peripheral NaV1.8 inhibition, minimizing central nervous system effects and abuse potential. Ongoing research is evaluating suzetrigine for chronic pain con- ditions including diabetic peripheral neuropathy and lumbosacral radiculopathy, though long-term efficacy and safety remain to be established. “Suzetrigine represents a promising nonopioid alternative for acute pain and has the potential to fill a significant gap in pain management,” according to study authors. “While initial results are encouraging, future studies are needed to define its role in chronic pain and multimodal analgesia, and to establish long- term safety.” Another review, published in the International Journal of Molecular Sciences last year, suggested, “The ongoing opioid epidemic in the United States high- lights the need for novel analgesics with reduced risk of misuse, dependence and adverse central nervous system effects. Suzetrigine (trade name Journavx), a first-in- class selective Nav1.8 (a sodium channel expressed in peripheral nociceptors) inhibitor, was approved by the FDA in early 2025 and marketed as the first non-opioid Source: The HCAHPS Survey, Pain Management, and Opioid Misuse. The CMS Perspective: Clarifying Facts, Myths, and Approaches. Presentation Slides. 2016. Available online: https://www.qualityreportingcenter.com/en/inpatient-quality-reporting-programs/hospital-value-based-purchasing-vbp-program/vbp-archived- events/vbp-event32/ (accessed on 18 August 2025).
View this content as a flipbook by clicking here.